CLINICAL OBSERVATION ON PROGNOSIS SURVIVAL RATE AND SIDE EFFECTS OF SEQUENTIAL RADIOTHERAPY AND CHEMOTHERAPY IN PATIENTS WITH STAGE II-III GASTRIC CANCER

被引:2
|
作者
Wang, Shumin [1 ]
Ping, Mei [1 ]
Zhang, Gehong [1 ]
Guo, Yarong [1 ]
Li, Yuanfei [1 ]
Jia, Junmei [1 ]
机构
[1] Shanxi Med Univ, Hosp 1, Dept Oncol, Taiyuan 030001, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2021年 / 37卷 / 02期
关键词
Stage II-III; gastric cancer; sequential chemoradiotherapy; prognostic survival rate; toxic and side effects;
D O I
10.19193/0393-6384_2021_2_137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the prognosis survival rate of patients with stage II-III gastric cancer treated by sequential radiotherapy and chemotherapy, and the clinical observation of the side effects of radiotherapy and chemotherapy. Methods: A total of 126 patients with stage II - III gastric cancer from April 2014 to August 2016 were randomly selected and randomly divided into a study group and control group according to the random number table method, with 63 patients in each group. The patients in the study group were treated with sequential radiotherapy (chemotherapy radiotherapy chemotherapy), whereas the patients in the control group were treated with simple chemotherapy. The clinical data, recurrence rate, distant metastasis rate, prognosis survival rate and the occurrence of side effects were compared between the study group and the control group. Results: there was no significant difference in age, gender, TNM stage and differentiation between the study group and the control group (P>0.05). Compared with the control group, the recurrence rate of patients in the study group was significantly lower, the overall prognostic survival rate was significantly higher (P < 0.05) and the distant metastasis rate had no significant difference (P > 0.05). There was no significant difference between the two groups (P > 0.05). The overall prognosis survival rate was significantly higher in the study group than in the control group. Compared with the control group, the patients in the study group had decreased nausea, vomiting, oral mucositis, appetite decline, leucopoenia, thrombocytopenia, etc., but there was no significant difference between the two groups (P > 0.05). The incidence of liver and kidney dysfunction and diarrhoea in the study group was significantly lower than that in the control group (P<0.05). Conclusion: The prognosis survival rate of patients with stage II-III gastric cancer undergoing sequential chemoradiotherapy is significantly higher than that of chemotherapy alone. However, in terms of the toxic and side effects of radiochemotherapy, sequential radiochemotherapy is safer.
引用
收藏
页码:903 / 907
页数:5
相关论文
共 50 条
  • [21] Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer
    Furukawa, Kenichiro
    Irino, Tomoyuki
    Makuuchi, Rie
    Koseki, Yusuke
    Nakamura, Kenichi
    Waki, Yuhei
    Fujiya, Keiichi
    Omori, Hayato
    Tanizawa, Yutaka
    Bando, Etsuro
    Kawamura, Taiichi
    Terashima, Masanori
    GASTRIC CANCER, 2019, 22 (04) : 864 - 872
  • [22] Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer
    Kenichiro Furukawa
    Tomoyuki Irino
    Rie Makuuchi
    Yusuke Koseki
    Kenichi Nakamura
    Yuhei Waki
    Keiichi Fujiya
    Hayato Omori
    Yutaka Tanizawa
    Etsuro Bando
    Taiichi Kawamura
    Masanori Terashima
    Gastric Cancer, 2019, 22 : 864 - 872
  • [23] Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer
    Ji, Woong Bae
    Hong, Kwang Dae
    Kim, Jung-Sik
    Joung, Sung-Yup
    Um, Jun Won
    Min, Byung-Wook
    CHEMOTHERAPY, 2018, 63 (01) : 8 - 12
  • [24] Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy
    Sumi Yun
    Jiwon Koh
    Soo Kyung Nam
    Yoonjin Kwak
    Sang-Hoon Ahn
    Joong Do Park
    Hyung-Ho Kim
    Woo Ho Kim
    Hye Seung Lee
    Cancer Immunology, Immunotherapy, 2021, 70 : 431 - 441
  • [25] Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?
    Korkmaz, Mustafa
    Eryilmaz, Melek Karakurt
    Er, Muhammed Muhiddin
    Kocak, Mehmet Zahid
    Demirkiran, Aykut
    Karaagac, Mustafa
    Araz, Murat
    Artac, Mehmet
    Kocak, Zahid Mehmet
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (03) : 962 - 969
  • [26] Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?
    Mustafa Korkmaz
    Melek Karakurt Eryılmaz
    Muhammed Muhiddin Er
    Mehmet Zahid Koçak
    Aykut Demirkıran
    Mustafa Karaağaç
    Murat Araz
    Mehmet Artaç
    Zahid Mehmet Koçak
    Journal of Gastrointestinal Cancer, 2023, 54 : 962 - 969
  • [27] Nomogram for predicting overall survival in stage II-III colorectal cancer
    Liu, Jungang
    Huang, Xiaoliang
    Yang, Wenkang
    Li, Chan
    Li, Zhengtian
    Zhang, Chuqiao
    Chen, Shaomei
    Wu, Guo
    Xie, Weishun
    Wei, Chunyin
    Tian, Chao
    Huang, Lingxu
    Jeen, Franco
    Mo, Xianwei
    Tang, Weizhong
    CANCER MEDICINE, 2020, 9 (07): : 2363 - 2371
  • [28] Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy
    Yun, Sumi
    Koh, Jiwon
    Nam, Soo Kyung
    Kwak, Yoonjin
    Ahn, Sang-Hoon
    Park, Joong Do
    Kim, Hyung-Ho
    Kim, Woo Ho
    Lee, Hye Seung
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (02) : 431 - 441
  • [29] Vitamin D Status and Survival in Stage II-III Colorectal Cancer
    Bao, Yichao
    Li, Yaqi
    Gong, Yan
    Huang, Qianxia
    Cai, Sanjun
    Peng, Junjie
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Neoadjuvant biweekly chemotherapy with liposomal doxorubicin and docetaxel in patients with stage II-III breast cancer
    Alvarez, I
    Modolell, A.
    Mayordomo, J., I
    Heras, L.
    Villadiego, K.
    Rolfo, C. D.
    Garcia-Bueno, J. M.
    Pica, P.
    Murillo, L.
    Morales, S.
    Valera, P.
    Florian, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S229 - S229